Convergent evolution of p38/MAPK activation in hormone resistant prostate cancer mediates pro-survival, immune evasive, and metastatic phenotypes
Kathryn E Ware,
Bhairavy J Puviindran,
Lorin A Crawford,
R. Garland Almquist,
Beatrice C Thomas,
Maya U Sheth,
Emanuel F. Petricoin,
David L Corcoran,
Steven R Patierno,
Justin M. Drake,
Andrew J Armstrong,
Jason A Somarelli
Posted 24 Apr 2020
bioRxiv DOI: 10.1101/2020.04.22.050385
Posted 24 Apr 2020
Adaptation of cancer cells to targeted therapy follows ecological paradigms observed in natural populations that encounter resource depletion and changing environments, including activation of pro-survival mechanisms, migration to new locations, and escape of predation. We identified the p38 MAPK pathway as a common molecular driver of these three responses during the adaptation to hormone therapy resistance in prostate cancer. The p38 pathway is activated in therapy-resistant cells and mechanistically drives these three convergent responses through sustained AR activity, enhanced invasion and metastasis, and immune evasion. Targeting p38 signaling may represent a new therapeutic strategy to treat men with metastatic, hormone therapy-resistant prostate cancer. ### Competing Interest Statement AJA receives consulting income and research support to Duke from Pfizer/Astellas, Bayer, Dendreon, Merck, AstraZeneca, and Janssen. He receives research support to Duke from BMS, Constellation, Gilead, Genentech/Roche. MP and EP are inventors on US Government and University assigned patents and patent applications that cover aspects of the technologies discussed such as Reverse Phase Protein Microarrays. As inventors, they are entitled to receive royalties as provided by US Law and George Mason University policy. MP and EP receive royalties from Avant Diagnostics. EP is consultant to and shareholder of Avant Diagnostics, Inc and Perthera, Inc. All other authors declare no competing interests.
- Downloaded 152 times
- Download rankings, all-time:
- Site-wide: 77,448 out of 89,671
- In cancer biology: 2,640 out of 3,162
- Year to date:
- Site-wide: 24,271 out of 89,671
- Since beginning of last month:
- Site-wide: 29,477 out of 89,671
Downloads over time
Distribution of downloads per paper, site-wide
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!